Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eli Lilly and Company has reported that the FDA Psychopharmacologic Drugs Advisory Committee has voted in favour of Zyprexa long-acting injection, which was shown to be effective and acceptably safe for the treatment and maintenance treatment of schizophrenia in adults.
Subscribe to our email newsletter
The committee reviewed data from a comprehensive clinical program comprising eight studies. Results from the clinical trials showed greater symptom improvement in Zyprexa long-acting injection (LAI) treated patients, compared with those on placebo. Due to the nature of the formulation of Zyprexa LAI, supplementation with oral antipsychotics was not needed to achieve or maintain effect in these studies.
John Hayes, vice president of Lilly Research Laboratories, said: “Due to the chronic and severe nature of the illness and the limited number of approved long-acting formulations, we believe that, if approved, Zyprexa LAI could be an important treatment option for this patient population, who struggle with taking their medication.”